Edwards Lifesciences Corporatio (EW) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Edwards Lifesciences Corporatio

NYSE•Healthcare•Medical Devices

$88.25-1.03(-0.01%)After hours

Market Cap

$50.87B

P/E

50.6x

P/S

7.8x

P/B

4.8x

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

How this company scores

GoodMetricSide Score: 69/100

Strongest: Balance Sheet & Red Flags (19/25); weakest: Profitability (15/25).

Profitability15/25

Growth16/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality19/25

Strengths

Growing revenueRising free cash flowStrong marginsLow leverage

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 50.6x5y range 8.8x – 181.9x

Currently above its 13-quarter median.

P/S · 7.8x5y range 6.7x – 15.6x

Currently near its 20-quarter median.

P/B · 4.8x5y range 4.1x – 14.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 16.6% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $50.87B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $6.51B
Q. Revenue: $1.74B
TTM EBITDA: $1.69B
TTM Op. Income: $1.45B
Q. Op. Income: $513.20M
TTM Net Income: $1.00B
Q. Net Income: $241.90M
EPS: $0.42
Shares Out.: $576.40M

$6.51B in TTM revenue grew 20.6% YoY, reaching $1.74B last quarter. TTM EBITDA of $1.69B and TTM operating income of $1.45B show growth is flowing through to the bottom line. TTM net income of $1.00B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 77.5%
EBITDA Margin: 31.9%
Op. Margin: 29.5%
Net Margin: 13.9%

Op. margin of 29.5% is up 2.6% YoY — cost efficiency is improving. Net margin at 13.9% and gross margin of 77.5% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 50.6x
P/S Ratio: 7.8x
P/B Ratio: 4.8x

At 50.6x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 7.8x and P/B of 4.8x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 357% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $13.87B
Cash: $2.91B
Long-Term Debt: $598.70M
Book Value: $10.62B
D/E Ratio: 0.1
Debt/EBITDA: 1.1

With $13.87B in assets and $598.70M in long-term debt, D/E is 0.1and book value is $10.62B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 1% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $651.90M
TTM Free Cash Flow: $1.43B
FCF Margin: 22.0%
FCF / Net Income: 1.4

TTM FCF of $1.43B on $651.90M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 144% — an improving trend.